Serina Therapeutics, Inc. (SER)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 1.5M 3M 4.5M FY17: 1.4M FY18: 1.4M FY19: 1.7M FY20: 361K FY21: 144K FY22: 34K FY23: 3.2M FY24: 56K FY25: 130K FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Gross Profit Annual

0 600K 1.2M 1.8M FY17: 1.2M FY18: 1M FY19: 1.5M FY20: 335K FY21: 125K FY22: 21K FY23: 102K FY17 FY18 FY19 FY20 FY21 FY22 FY23

Operating Income Annual

-27M -18M -9M 0 9M 18M 27M FY17: -6.7M FY18: -11.2M FY19: -12.6M FY20: -10.1M FY21: -7.9M FY22: -7M FY23: -3.1M FY24: -17M FY25: -24M FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Net Income Annual

-21M -14M -7M 0 7M 14M 21M FY17: -6.6M FY18: -7.5M FY19: -12.2M FY20: -10.9M FY21: -8.7M FY22: -10.5M FY23: 5.3M FY24: -11.1M FY25: -19.2M FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Cost of Revenue Annual

0 150K 300K 450K FY17: 168K FY18: 364K FY19: 244K FY20: 26K FY21: 19K FY22: 13K FY23: 40K FY17 FY18 FY19 FY20 FY21 FY22 FY23

Operating Cash Flow Annual

-21M -14M -7M 0 7M 14M 21M FY17: -6.3M FY18: -8M FY19: -10.2M FY20: -7.8M FY21: -7.9M FY22: -5.9M FY23: -2.5M FY24: -17.1M FY25: -18M FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Free Cash Flow Annual

-21M -14M -7M 0 7M 14M 21M FY17: -6.3M FY18: -8M FY19: -10.8M FY20: -7.8M FY23: -3M FY24: -17.2M FY25: -18M FY17 FY18 FY19 FY20 FY23 FY24 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 15M 30M 45M FY21: 37.9M FY22: 1.1K FY23: 7.4M FY24: 7.4M FY25: 10.2M FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q4 '18: -0.22 Q1 '19: -0.30 Q2 '19: -0.32 Q3 '19: -0.35 Q4 '19: -0.34 Q1 '20: -0.33 Q2 '20: -0.32 Q3 '20: -0.30 Q4 '20: -0.29 Q1 '21: -0.27 Q2 '24: -4.48 Q3 '24: -4.58 Q4 '25: -1.91 Q1 '26: -2.00 Q2 '26: -1.89 Q4 '18 Q2 '19 Q4 '19 Q2 '20 Q4 '20 Q2 '24 Q4 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.